Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: ACLS THER

Market Cap 609M 525M 483M 453M 851M 57.55B 860M 5.71B 2.23B 28.18B 2.29B 2.24B 97.52B P/E Ratio 2026 *
-6.72x
P/E Ratio 2027 * -5.47x
Enterprise Value 473M 408M 375M 352M 662M 44.73B 668M 4.44B 1.73B 21.91B 1.78B 1.74B 75.8B EV / Sales 2026 *
82.9x
EV / Sales 2027 * 90.3x
Free-Float
97.72%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 56 17/01/2024
President 67 18/11/2024
Director of Finance/CFO 39 01/01/2023
Director TitleAgeSince
Chairman 56 01/01/2023
Chairman 60 01/06/2019
Director/Board Member 50 01/09/2014
Change 5-day change 1-year change 3-year change Capi.($)
-0.08%+0.34%+57.44%+108.50% 54.92B
-0.34%+3.51%+45.55%+40.16% 44.31B
+0.29%+6.20%-14.80%-19.65% 22.96B
-0.40%+3.49%-1.29%+387.06% 21.12B
-2.91%+0.27%+13.28%-36.73% 16.31B
-1.14%-2.51%+6.48%-41.35% 15.19B
-0.24%+2.44%+27.43%+177.49% 13.32B
+1.48%+9.81%+19.29% - 12.48B
+0.32%+2.81%+96.37%+213.49% 11.21B
Average -0.23%+2.75%+27.75%+103.62% 23.54B
Weighted average by Cap. -0.22%+2.86%+32.14%+95.28%

Financials

2026 *2027 *
Net sales 5.71M 4.92M 4.53M 4.25M 7.99M 540M 8.07M 53.57M 20.93M 264M 21.44M 20.98M 915M 5.36M 4.62M 4.25M 3.99M 7.49M 506M 7.56M 50.25M 19.63M 248M 20.11M 19.68M 858M
Net income -84.78M -73.07M -67.25M -63.09M -119M -8.01B -120M -795M -311M -3.92B -318M -311M -13.58B -103M -88.36M -81.32M -76.29M -143M -9.69B -145M -961M -376M -4.74B -385M -377M -16.42B
Net Debt -136M -117M -108M -101M -190M -12.82B -191M -1.27B -497M -6.28B -509M -498M -21.72B -125M -108M -99.08M -92.94M -175M -11.8B -176M -1.17B -458M -5.78B -469M -459M -20B
Logo ACLS THER
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing novel small and large molecule product candidates for immuno-inflammatory diseases. Its proprietary KINect drug discovery platform coupled with its integrated discovery approach to small and large molecules enables the Company to identify and advance product candidates. It provides contract research services to third parties enabled by its early-stage research and development expertise. The contract research segment is engaged in the provision of laboratory services. Its product candidate pipeline includes Bosakitug (ATI-045), ATI-2138 and ATI-052. The Bosakitug (ATI-045) is an investigational, novel, humanized anti-Thymic stromal lymphopoietin (TSLP) monoclonal antibody that specifically binds to human TSLP, blocking its interaction with the receptor complex and disrupting signal transduction. Its other investigational product candidate is Lepzacitinib (ATI-1777).
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!